Who is sponsoring NCT03044756?

NCT03044756 is sponsored by Assiut University.

What drugs are being tested in NCT03044756?

Interventions in NCT03044756: Omit Citrotide 0.25 dose on the day of triggering of ovulation.

What condition does NCT03044756 study?

NCT03044756 studies Pituitary Downregulation.

Is NCT03044756 still recruiting?

NCT03044756 is currently status unknown. Last updated 7 February 2017.

Last reviewed 2017-02-07 · How we verify

NCT03044756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

Status unknown Phase 2, PHASE3 Last updated 7 February 2017

What this trial tests

Phase 2, PHASE3 trial testing Omit Citrotide 0.25 dose on the day of triggering of ovulation in Pituitary Downregulation in 100 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
30 August 2017

30 December 2017

Quick facts

Lead sponsor	Assiut University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	1 January 2017
Primary completion	30 August 2017
Estimated completion	30 December 2017
Sites	2 locations across Egypt

Drugs / interventions tested

Omit Citrotide 0.25 dose on the day of triggering of ovulation — full drug profile →

Conditions studied

Pituitary Downregulation — all drugs for Pituitary Downregulation →

Sponsor

Assiut University

Who can join

Adults 20 to 35, female only, with Pituitary Downregulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03044756 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 7 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03044756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing